arrow
F

Frank Follmann

Statens Serum Institut
H指数:27
被引数:2,925

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trial

疫苗H56:IC31在降低HIV阴性、成功接受药物敏感型肺结核治疗成人中结核病复发率方面的免疫原性、安全性与有效性:一项双盲、随机、安慰剂对照的2b期试验

2025-03-050
PRE
MINCLE and TLR9 agonists synergize to induce Th1/Th17 vaccine memory and mucosal recall in mice and non-human primates
2024-10-170
OAAI
Multimodal mucosal and systemic immune characterization of a non-human primate trachoma model highlights the critical role of local immunity during acute phase disease

非人类灵长类动物沙眼模型的多模式粘膜和全身免疫表征突出了局部免疫在急性期疾病中的关键作用

2024-08-020
OAAI
An investigation of trachoma vaccine regimens by the chlamydia vaccine CTH522 administered with cationic liposomes in healthy adults (CHLM-02): a phase 1, doubleblind trial
2024-08-016
OAAI
Multi-component prime-boost Chlamydia trachomatis vaccination regimes induce antibody and T cell responses and accelerate clearance of infection in a non-human primate model
2022-11-2313
OAAI
Protection against SARS-CoV-2 transmission by a parenteral prime-Intranasal boost vaccine strategy

通过肠胃外prime-鼻内加强疫苗策略防止SARS-CoV-2传播

2022-10-0118
OAAI
Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

以CAF01脂质体或氢氧化铝为佐剂的衣原体疫苗候选CTH522的安全性和免疫原性: 首次在人类,随机,双盲,安慰剂对照,1期试验

2019-10-01141
PREAI
Genital Infiltrations of CD4+ and CD8+ T Lymphocytes, IgA+ and IgG+ Plasma Cells and Intra-Mucosal Lymphoid Follicles Associate With Protection Against Genital Chlamydia trachomatis Infection in Minipigs Intramuscularly Immunized With UV-Inactivated Bacteria Adjuvanted With CAF01
2019-02-0810
OAAI